{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:25:48Z","timestamp":1784903148822,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"DOI":"10.7759\/cureus.102834","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:34:41Z","timestamp":1770046481000},"source":"Crossref","is-referenced-by-count":2,"title":["Antibody-Negative Nivolumab-Induced Autoimmune Encephalitis: A Case Report and Review of Seronegative Presentations"],"prefix":"10.7759","author":[{"given":"Myriam","family":"Hamza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon KM","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 62:29-39. 10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01522-x","article-title":"Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis","volume":"43","author":"Wu Z","year":"2025","unstructured":"Wu Z, Lei H, Li R, Liu X, Wang C. Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis. Invest New Drugs. 2025, 43:293-300. 10.1007\/s10637-025-01522-x","journal-title":"Invest New Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin J","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017, 22:709-18. 10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.009","article-title":"Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study","volume":"175","author":"M\u00fcller-Jensen L","year":"2022","unstructured":"M\u00fcller-Jensen L, Zierold S, Versluis JM, et al.. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer. 2022, 175:224-35. 10.1016\/j.ejca.2022.08.009","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco R","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, et al.. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021, 78:864-73. 10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan V","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology. 2021, 97:e191-202. 10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20377","article-title":"Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature","volume":"150","author":"Stuby J","year":"2020","unstructured":"Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020, 150:w20377. 10.4414\/smw.2020.20377","journal-title":"Swiss Med Wkly"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1621045","article-title":"Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER","volume":"15","author":"Di X","year":"2025","unstructured":"Di X, Shi X, Gai F, Wang J. Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER. Front Oncol. 2025, 15:1621045. 10.3389\/fonc.2025.1621045","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus F","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al.. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016, 15:391-404. 10.1016\/S1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine ZS","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al.. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005, 53:695-9. 10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.026","article-title":"Immune checkpoint inhibitor-associated CNS autoimmune\u00a0disorder (ICICAD)\u00a0following nivolumab treatment: a\u00a0new entity of drug-induced autoimmune encephalitis?","volume":"87","author":"Strik H","year":"2017","unstructured":"Strik H, Keber U, Hammoud WA, et al.. Immune checkpoint inhibitor-associated CNS autoimmune\u00a0disorder (ICICAD)\u00a0following nivolumab treatment: a\u00a0new entity of drug-induced autoimmune encephalitis?. Eur J Cancer. 2017, 87:205-8. 10.1016\/j.ejca.2017.09.026","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8895-17","article-title":"Acute cerebellar ataxia induced by nivolumab","volume":"56","author":"Kawamura R","year":"2017","unstructured":"Kawamura R, Nagata E, Mukai M, et al.. Acute cerebellar ataxia induced by nivolumab. Intern Med. 2017, 56:3357-9. 10.2169\/internalmedicine.8895-17","journal-title":"Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000477162","article-title":"PD-1 checkpoint inhibitor associated autoimmune encephalitis","volume":"10","author":"Schneider S","year":"2017","unstructured":"Schneider S, Potthast S, Komminoth P, Schwegler G, B\u00f6hm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017, 10:473-8. 10.1159\/000477162","journal-title":"Case Rep Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00108","article-title":"Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature","volume":"9","author":"Leitinger M","year":"2018","unstructured":"Leitinger M, Varosanec MV, Pikija S, et al.. Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature. Front Immunol. 2018, 9:108. 10.3389\/fimmu.2018.00108","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577350","article-title":"Nivolumab-induced seronegative encephalitis","volume":"347","author":"Cabral G","year":"2020","unstructured":"Cabral G, Ladeira F, Gil N. Nivolumab-induced seronegative encephalitis. J Neuroimmunol. 2020, 347:577350. 10.1016\/j.jneuroim.2020.577350","journal-title":"J Neuroimmunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000369","article-title":"Encephalitis associated with immune checkpoint inhibitor treatment in patients with melanoma","volume":"44","author":"Mart\u00ednez-Vila C","year":"2021","unstructured":"Mart\u00ednez-Vila C, Laguna JC, Segui E, et al.. Encephalitis associated with immune checkpoint inhibitor treatment in patients with melanoma. J Immunother. 2021, 44:204-7. 10.1097\/CJI.0000000000000369","journal-title":"J Immunother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101011","article-title":"Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study","volume":"44","author":"Farina A","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Fourier A, et al.. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet Reg Health Eur. 2024, 44:101011. 10.1016\/j.lanepe.2024.101011","journal-title":"Lancet Reg Health Eur"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx252","article-title":"Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient","volume":"28","author":"Ito M","year":"2017","unstructured":"Ito M, Fujiwara S, Fujimoto D, et al.. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol. 2017, 28:2318-9. 10.1093\/annonc\/mdx252","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207746","article-title":"Survival analysis of immunotherapy effects on relapse rate in pediatric and adult autoimmune encephalitis","volume":"101","author":"Yang JH","year":"2023","unstructured":"Yang JH, Liu EN, Nguyen L, Dunn-Pirio A, Graves JS. Survival analysis of immunotherapy effects on relapse rate in pediatric and adult autoimmune encephalitis. Neurology. 2023, 101:e2300-13. 10.1212\/WNL.0000000000207746","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442427-antibody-negative-nivolumab-induced-autoimmune-encephalitis-a-case-report-and-review-of-seronegative-presentations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:34:42Z","timestamp":1770046482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442427-antibody-negative-nivolumab-induced-autoimmune-encephalitis-a-case-report-and-review-of-seronegative-presentations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.102834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}